174 related articles for article (PubMed ID: 27130560)
1. Impact of metformin on metastases in patients with breast cancer and type 2 diabetes.
Jacob L; Kostev K; Rathmann W; Kalder M
J Diabetes Complications; 2016 Aug; 30(6):1056-9. PubMed ID: 27130560
[TBL] [Abstract][Full Text] [Related]
2. The effect of metformin on breast cancer outcomes in patients with type 2 diabetes.
Oppong BA; Pharmer LA; Oskar S; Eaton A; Stempel M; Patil S; King TA
Cancer Med; 2014 Aug; 3(4):1025-34. PubMed ID: 24944108
[TBL] [Abstract][Full Text] [Related]
3. Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
Bowker SL; Lin M; Eurich DT; Johnson JA
Can J Diabetes; 2017 Apr; 41(2):204-210. PubMed ID: 27908558
[TBL] [Abstract][Full Text] [Related]
4. Associations between diabetes medication use and risk of second breast cancer events and mortality.
Calip GS; Yu O; Hoskins KF; Boudreau DM
Cancer Causes Control; 2015 Aug; 26(8):1065-77. PubMed ID: 25956271
[TBL] [Abstract][Full Text] [Related]
5. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
Dombrowski S; Kostev K; Jacob L
Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
[TBL] [Abstract][Full Text] [Related]
6. Type 2 diabetes, breast cancer specific and overall mortality: Associations by metformin use and modification by race, body mass, and estrogen receptor status.
Lee KN; Torres MA; Troeschel AN; He J; Gogineni K; McCullough LE
PLoS One; 2020; 15(5):e0232581. PubMed ID: 32369516
[TBL] [Abstract][Full Text] [Related]
7. Effect of different glucose-lowering therapies on cancer incidence in type 2 diabetes: An observational population-based study.
Vicentini M; Ballotari P; Giorgi Rossi P; Venturelli F; Sacchettini C; Greci M; Mangone L; Pezzarossi A; Manicardi V
Diabetes Res Clin Pract; 2018 Sep; 143():398-408. PubMed ID: 29807100
[TBL] [Abstract][Full Text] [Related]
8. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
Kowall B; Stang A; Rathmann W; Kostev K
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):865-74. PubMed ID: 26132313
[TBL] [Abstract][Full Text] [Related]
9. The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes.
Vissers PA; Cardwell CR; van de Poll-Franse LV; Young IS; Pouwer F; Murray LJ
Breast Cancer Res Treat; 2015 Apr; 150(2):427-37. PubMed ID: 25762476
[TBL] [Abstract][Full Text] [Related]
10. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
Göke R; Gruenberger JB; Bader G; Dworak M
Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
[TBL] [Abstract][Full Text] [Related]
11. Metformin use associated with lower risk of cancer in patients with diabetes mellitus type 2.
Kusturica J; Kulo Ćesić A; Gušić E; Maleškić S; Rakanović-Todić M; Šečić D
Med Glas (Zenica); 2017 Aug; 14(2):176-181. PubMed ID: 28698536
[TBL] [Abstract][Full Text] [Related]
12. An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet.
Glueck CJ; Goldenberg N; Sieve L; Wang P
Metabolism; 2008 Jul; 57(7):954-60. PubMed ID: 18555837
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer risk for women with diabetes and the impact of metformin: A meta-analysis.
Lu Y; Hajjar A; Cryns VL; Trentham-Dietz A; Gangnon RE; Heckman-Stoddard BM; Alagoz O
Cancer Med; 2023 May; 12(10):11703-11718. PubMed ID: 36533539
[TBL] [Abstract][Full Text] [Related]
14. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
15. Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus.
Hui T; Shang C; Yang L; Wang M; Li R; Song Z
Sci Rep; 2021 May; 11(1):10034. PubMed ID: 33976288
[TBL] [Abstract][Full Text] [Related]
16. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
Wahlqvist ML; Lee MS; Hsu CC; Chuang SY; Lee JT; Tsai HN
Parkinsonism Relat Disord; 2012 Jul; 18(6):753-8. PubMed ID: 22498320
[TBL] [Abstract][Full Text] [Related]
17. Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes.
Tseng CH
Breast Cancer Res Treat; 2014 Jun; 145(3):785-90. PubMed ID: 24816805
[TBL] [Abstract][Full Text] [Related]
18. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.
Tsilidis KK; Capothanassi D; Allen NE; Rizos EC; Lopez DS; van Veldhoven K; Sacerdote C; Ashby D; Vineis P; Tzoulaki I; Ioannidis JP
Diabetes Care; 2014 Sep; 37(9):2522-32. PubMed ID: 24898303
[TBL] [Abstract][Full Text] [Related]
19. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
20. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus.
Kuan YC; Huang KW; Lin CL; Hu CJ; Kao CH
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):77-83. PubMed ID: 28583443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
